In conclusion, our study suggests that GLP1-RA treatments work equally well in individuals carrying common nonsynonymous mutations in the GLP1R gene and in individuals at high genetic risk for BMI and T2D. Here, GLP1R is linked to type 2 diabetes mellitus.